Abeona Therapeutics Inc. ABEO
Set alert
4.35 USD -0.21 -4.61%
At close · Oct 30
4.35 0.00 0.00%
After hours · Oct 30, 4:10 PM ET
4.31 Day range 4.53
4.17 52-week range 7.46
- YTD
- -17.46%
- 1 year
- -14.37%
- Open
- 4.50
- Prev close
- 4.56
- Mkt cap
- 248.75M
- Vol
- 783.43K
- Avg vol
- 1.35M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.31
- High
- 4.53
- Forward P/E
- -3.84
- Beta
- 1.50
- Short ratio
- 10.79
- Inst. own
- 77.54%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.15
- 200-d avg
- 5.64
- 1y target
- 16.75
2Y chart
Events in this range
- Oct 31, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 14, 2024Earnings: -0.31; estimate -0.38; surprise 18.42%
- Nov 25, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (94)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 19, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 8 months ago |
| SMA: Bullish | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 9 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 26, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 14, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 30, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| RSI: Oversold | Sep 30, 2025 | 1 year ago |
| RSI: Oversold | Sep 25, 2025 | 1 year ago |
| RSI: Oversold | Sep 19, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 12, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jun 26, 2025 | 1 year ago |
| SMA: Bullish | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 29, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| RSI: Overbought | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Feb 11, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| RSI: Oversold | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
Key statistics
- Market cap
- 246.92M
- Enterprise value
- 158.18M
- Trailing P/E
- 0.00
- Forward P/E
- -3.84
- PEG ratio
- 0.00
- Price / book
- 10.16
- EPS (TTM)
- -2.05
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.50M
- Total cash
- 122.71M
- Total debt
- 23.16M
- Return on equity
- -127.38%
- Shares outstanding
- 43.47M
- Short % of float
- 6.29%
- 50-day average
- 6.15
- 200-day average
- 5.64
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.75 +285.1% upside
Now 4.35
- Target (low)
- 9.50
- Target (mean)
- 16.75
- Target (high)
- 21.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34.
Financials — quick view
ABEO Revenue — quarterly 11.38M
ABEO Net income — quarterly -20.19M
ABEO EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.38 | -0.31 | +0.07 | +18.42% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.75 | -0.42 | -127.27% |
| May 15, 2024 | Mar 1, 2024 | -0.47 | -0.53 | -0.06 | -12.77% |
| Mar 18, 2024 | Dec 1, 2023 | -0.51 | -0.64 | -0.13 | -25.49% |
| Nov 13, 2023 | Sep 1, 2023 | -0.53 | -0.48 | +0.05 | +9.43% |
| Aug 8, 2023 | Jun 1, 2023 | -0.66 | -0.44 | +0.22 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 29, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 3, 2024 | HC Wainwright & Co. | init | — | Buy |
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- abeonatherapeutics.com
News
- Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock Has Consensus Target Price of $21.00
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
- Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
- Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Your note
Sign in to keep a note on ABEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLAND LEILA | Director | Stock Award(Grant) | Aug 25, 2024 | 118,265 |
| ALVINO MARK J. | Director | Stock Award(Grant) | Aug 25, 2024 | 72,334 |
| AMOROSO MICHAEL | Director | Stock Award(Grant) | Aug 25, 2024 | 144,365 |
| CHARLES FAITH L. | Director | Stock Award(Grant) | Aug 25, 2024 | 113,731 |
| CROMBEZ ERIC M.D. | Director | Stock Award(Grant) | Aug 12, 2024 | 11,044 |
| O'MALLEY BRENDAN M | General Counsel | Stock Award(Grant) | Jul 7, 2024 | 280,364 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8.48% | 3,685,503 | 20.93M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 7.90% | 3,432,637 | 19.50M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.48% | 3,249,994 | 18.46M | Sep 29, 2024 |
| Millennium Management Llc | 5.29% | 2,301,628 | 13.07M | Sep 29, 2024 |
| Vanguard Group Inc | 4.62% | 2,007,626 | 11.40M | Sep 29, 2024 |
| Vivo Capital, LLC | 4.24% | 1,842,751 | 10.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.84% | 1,232,465 | 7.00M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.62% | 703,062 | 3.99M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.94% | 408,584 | 2.32M | Sep 29, 2024 |
| abrdn Life Sciences Investors | 0.75% | 326,995 | 1.86M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.53% | 229,139 | 1.30M | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 89,297 | 507.21K | Oct 30, 2024 |